Trial Profile
Open-label Phase 2 study evaluating efficacy and safety of SAR566658 treatment in patients with CA6 positive metastatic Triple Negative Breast Cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs SAR 566658 (Primary)
- Indications Advanced breast cancer; Triple negative breast cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Sanofi
- 14 Sep 2021 Status changed from completed to discontinued (Study discontinued considering the limited clinical benefit combined with a higher thanexpected rate of known non-serious ophthalmological event.).
- 28 Feb 2019 This trial has been discontinued in Netherlands (End Date 2018-08-13).
- 25 Jan 2019 This trial has been discontinued in Spain, according to European Clinical Trials Database record.